TMCI — Treace Medical Concepts Cashflow Statement
0.000.00%
- $406.83m
- $392.11m
- $209.36m
- 52
- 37
- 54
- 45
Annual cashflow statement for Treace Medical Concepts, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.67 | -20.6 | -42.8 | -49.5 | -55.7 |
| Depreciation | |||||
| Non-Cash Items | 3.28 | 4 | 15.8 | 19.3 | 35.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.32 | -1.33 | -5.81 | -9.74 | -25.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.49 | -17.2 | -30.6 | -34.6 | -37.2 |
| Capital Expenditures | -1.07 | -2.71 | -14.8 | -11.5 | -11.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -61.7 | -69.8 | 47 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.07 | -2.71 | -76.5 | -81.3 | 35.4 |
| Financing Cash Flow Items | -0.179 | 0 | -0.989 | -0.013 | -0.268 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.5 | 108 | 20.8 | 109 | 0.16 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.94 | 87.8 | -86.4 | -6.49 | -1.63 |